1 / 42

Advances in Lymphoma

Advances in Lymphoma. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Ibrutinib Monotherapy. GS-9973 and Idelasib in Patients With R/R CLL. ABT-199 in Patients With R/R CLL/SLL. Hodgkin Lymphoma. ABVD With and Without Bleomycin and/or Dacarbazine.

declan-harding
Download Presentation

Advances in Lymphoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Advances in Lymphoma

  2. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  3. Ibrutinib Monotherapy

  4. GS-9973 and Idelasib in Patients With R/R CLL

  5. ABT-199 in Patients With R/R CLL/SLL

  6. Hodgkin Lymphoma

  7. ABVD With and Without Bleomycin and/or Dacarbazine

  8. Brentuximab Vedotin Followed by ABVD in Patients With Untreated NHL

  9. Single-Agent Brentuximab Vedotin in R/R Hodgkin Lymphoma

  10. Follicular Lymphoma

  11. Prognostic Value of PET-CT After FL Therapy in FL

  12. FOLL05, 5-Year Follow-up

  13. Alliance/CALGB 50803Lenalidomide Plus Rituximab for Untreated FL

  14. ROMULUSPolatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients With R/R FL

  15. Diffuse Large B-Cell Lymphoma

  16. Two Different R-CHOP Variants

  17. ABT-199 for DLBCL

  18. Monitoring MRD Using Cellular and Acellular Blood DNA

  19. Mantle Cell Lymphoma

  20. R-CHOP vs VR-CAP for BMT-Ineligible Newly Diagnosed Patients With MCL

  21. Subcutaneous Bortezomib in Relapsed MCL

  22. Safety of Ibrutinib in R/R MCL

  23. T-Cell Lymphoma

  24. Alisertib for PTCL

  25. Response to Romidepsin by Number of Lines of Prior Therapies in R/R PTCL

  26. Topical SHP-141 for CTCL

  27. Outcomes of Patients With PTCL From the BCCA Registry After Standard Chemotherapy

  28. Abbreviations

  29. Abbreviations (cont)

  30. Abbreviations (cont)

  31. References

  32. References (cont)

  33. References (cont)

  34. References (cont)

  35. References (cont)

  36. References (cont)

  37. References (cont)

  38. References (cont)

  39. References (cont)

  40. References (cont)

  41. References (cont)

  42. References (cont)

More Related